Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors (Q44355651)

2 December 2017

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors (English)

1 reference

2 December 2017

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Ignat Drozdov

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Lisa Bodei

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Mark Kidd

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Chiara M Grana

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Marta Cremonesi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Christopher Lepensky

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Dik J Kwekkeboom

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Richard P Baum

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Eric P Krenning

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Irvin M Modlin

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

2 October 2014

1 reference

2 December 2017

15

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

5-19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273832%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-014-2893-5

4 June 2020

exact match

0 references

cites work

Peptide receptor therapies in neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

90Y-edotreotide for metastatic carcinoid refractory to octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Recommendations for management of patients with neuroendocrine liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

The evolving challenge of therapy-related myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

End-stage renal disease after treatment with 90Y-DOTATOC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Gender differences in kidney function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Renal function assessment in the era of chronic kidney disease: renewed emphasis on renal function centered patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Therapy-related myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2893-5

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

21 January 2018

1 reference

12 December 2020

Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy

1 reference

12 December 2020

Dosimetry for treatment with radiolabelled somatostatin analogues. A review.

1 reference

12 December 2020

Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney

1 reference

12 December 2020

Dosimetry in nuclear medicine therapy: radiobiology application and results

1 reference

12 December 2020

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020